ICON-2

After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal
Endpoints
Thu, 05/16/19 - 10:25 am
Exelixis
Cabometyx
ICON-2
Iconic Therapeutics
antibody-drug conjugate